氟吡啶-18F PET心肌灌注显像改善肥胖患者冠状动脉疾病评估:AURORA 3期研究预设亚组分析
基于AURORA 3期试验的预设亚组分析,纳入604例疑似冠心病患者,其中298例肥胖(BMI≥30 kg/m2)。结果显示氟吡啶-18F PET MPI在肥胖患者中达到主要终点,诊断效能高于99mTc-SPECT,且肥胖与非肥胖患者间无显著差异。
要点
- 氟吡啶-18F PET MPI在肥胖患者中敏感性70.1%–88.0%,特异性53.6%–74.0%。
- 肥胖患者中PET敏感性显著高于SPECT(Reader 1: 72.6% vs 60.7%,P=0.01;Reader 3: 88.0% vs 74.4%,P=0.002)。
- 肥胖与非肥胖患者诊断效能无显著差异(敏感性P=0.26,特异性P=0.25,准确性P=1.0)。
核心结论
- 氟吡啶-18F PET MPI在肥胖患者中诊断冠心病效能高,且不劣于非肥胖患者。
研究设计与样本
- AURORA 3期试验的预设二次分析,纳入604例疑似冠心病患者,48个中心,肥胖组298例(BMI≥30 kg/m2)。
主要发现
- 肥胖患者中氟吡啶-18F PET MPI达到主要终点,两名阅片者 lower 95% CI 均大于60% 且单侧 P<0.025。
- 肥胖患者中PET敏感性70.1%–88.0%,特异性53.6%–74.0%(3名阅片者范围)。
- Reader 1和3显示PET敏感性显著高于SPECT,特异性非劣效。
- 各BMI类别中PET诊断效能均高于SPECT。
关键数值与推荐
- 主要终点:以定量冠状动脉造影≥50%狭窄为冠心病标准,要求两名阅片者敏感性/特异性 lower 95% CI 均大于60%。
- 肥胖定义:BMI≥30 kg/m2。
临床怎么用
- 肥胖疑似冠心病患者可考虑氟吡啶-18F PET MPI以获得优于SPECT的诊断效能。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Noninvasive assessment of coronary artery disease (CAD) in obese patients is challenging due to suboptimal image quality. We performed a prespecified secondary analysis of obese patients from the second Phase III trial of flurpiridaz-18F positron emission tomography (PET). METHODS: In total, 604 patients with suspected CAD underwent flurpiridaz-18F PET and 99mTc-single-photon emission computerized tomography (SPECT) myocardial perfusion imaging (MPI) before invasive coronary angiography (ICA) across 48 sites. MPI images were interpreted by three blinded experts. The primary endpoint was sensitivity and specificity for diagnosing CAD (≥50% stenosis on quantitative coronary angiography), requiring the lower 95% confidence interval to exceed 60% by 2 same blinded expert core lab readers, assessed using one-sided z-test (α = 0.025). Sensitivity and specificity were compared between PET and SPECT and between obese (body mass index [BMI] ≥30 kg/m2) and nonobese patients. RESULTS: Of 578 evaluable patients, 298 (51.6%) were obese (mean age: 62.0 years, 64.4% male, mean BMI: 35.6 kg/m2) and 117 (39.3%) had CAD by ICA. In obese patients, flurpiridaz-18F PET MPI met the primary endpoint, with lower 95% confidence limits greater than 60% and one-sided P < 0.025 by the same 2 readers (Readers 1 and 2). Sensitivity across 3 readers ranged from 70.1% to 88.0% and specificity ranged from 53.6% to 74.0%. In obese patients, flurpiridaz-18F PET MPI showed significantly higher sensitivity compared to 99ᵐTc-SPECT MPI by Readers 1 and 3 (Reader 1: 72.6% vs 60.7%, P = 0.01; Reader 3: 88.0% vs 74.4%, P = 0.002), with non-inferior specificity by the same two readers (Reader 1: 68.0% vs 61.3%; Reader 3: 53.6% vs 50.8%; P < 0.01 for noninferiority, for both), noting that the primary endpoint was met by a partially overlapping reader pair (Readers 1 and 2). Diagnostic performance of flurpiridaz-18F PET was higher than SPECT across BMI categories. No statistically significant difference in diagnostic performance was observed between obese and nonobese patients (Sensitivity P = 0.26, specificity P = 0.25 and accuracy P = 1.0). CONCLUSION: Flurpiridaz-18F PET MPI demonstrates high diagnostic efficacy for detecting CAD across BMI categories in obese patients compared to ICA and 99mTc-SPECT, with no loss of diagnostic performance in obese relative to nonobese patients. CLINICAL TRIAL REGISTRATION: NCT03354273.
引用
- Patel KK, Maddahi J, Agostini D, et al. Improved assessment of coronary artery disease in obese patients with flurpiridaz-18F positron emission tomography myocardial perfusion imaging: A prespecified subgroup analysis of the AURORA phase 3 study. J Nucl Cardiol. 2026. PMID: 42128226. doi:10.1016/j.nuclcard.2026.102741
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。